所在系室：药理学系
E-Mail：Zhudi@fudan.edu.cn
人才项目
2024年，国家高层次人才计划科创领军
2020年，复旦大学卓识人才培育计划
2016年，国家海外高层次人才计划青年计划
获得奖项
2025年 上海药学科技奖优秀成果奖
2024年 复旦大学优秀博士学位论文指导导师
2024年 第三十五届上海市优秀发明选拔赛优秀发明铜奖
2023年 中国抗癌协会科技奖二等奖
2022年 上海生物工程学会“东富龙”生物工程优秀青年科学家奖
2019年 增爱·长木学术奖，增爱中国基金会
2010年 欧洲生物化学学会联盟, FEBS Youth Travel Fellowship
工作经历
2011.01—2015.06 美国哈佛大学Dana-Farber 癌症研究所博士后
2015.07—2016.05 美国哈佛大学Dana-Farber 癌症研究所讲师（junior faculty）
2016.10— 2021.07 复旦大学药学院，博士生导师
2021.08— 至今 复旦大学基础医学院，博士生导师
代表性论文
Wu SY, Zhu YY, Sun JL, Wang CY, Wang YL, Nie YY, Song F, Huang X, Chen Z, He T, Shen LA, Xu Y, Huang C, Qiu SJ, Zhou J, Zhu AX*, Fan J*, Zhu D*, Hu B*, Yang XR*. Targeting tumor-intrinsic BCL9 reverses immunotherapy resistance by eliciting macrophage-mediated phagocytosis and antigen presentation. Nat Commun. 2025,16(1):10039.
Yang F, Li A, Zhu Y, Zhou Y, Tian E, Yang M, Zhou Q, Yang D, Wang MW*, Mei F*, Zhu D*. GATA1-mediated Notch signaling augment antitumor immunity of CD11b+CD27- natural killer cells maturation via BCL9/β-catenin signal.Cell Rep.2025,44(5):115708.
Zhang H; Liu C; Chen Q; Shen L; Xiao W; Li J; Wang Y*; Zhu D*; Zhang Q*; Li J*.Discovery of Novel 3-Phenylpiperidine Derivatives Targeting the β‑Catenin/B-Cell Lymphoma 9 (BCL9) Interaction as a Single Agent and in Combination with Anti-PD-1 Antibody for the Treatment of Colorectal Cancer. Journal of Medicinal Chemistry, 2023, 66(2):1349-1379.
Xu Y; Wei Z; Feng M; Zhu D; Mei S; Wu Z; Feng Q; Chang W; Ji M; Liu C; Zhu Y; Shen L; Yang F; Chen Y; Feng Y; Xu J*; Zhu D*.Tumor-infiltrated activated B cells suppress liver metastasis of colorectal cancers. Cell Reports, 2022 40(9)：1-25.
Hu, B., Yu, M., Ma, X., Sun, J., Liu, C., Wang, C., Wu, S., Fu, P., Yang, Z., He, Y., Zhu, Y., Huang, C., Yang, X., Shi, Y., Qiu, S., Sun, H., Zhu, A., Zhou, J., Xu, Y., Zhu, D.*, Fan, J.* Interferon-α potentiates anti-PD-1 efficacy by remodeling glucose metabolism in the hepatocellular carcinoma microenvironment. Cancer Discov. 2022,12(7):1718-1741.
Feng, M., Wu, Z., Zhou, Y., Wei, Z., Tian, E., Mei, S., Zhu, Y., Liu, C., He, F., Li, H., Xie, C., Jin, J., Dong, J., Yang, D., Yu, K., Qian, J., Lambrechts, D.*, Wang, M.*, Zhu, D.* BCL9 regulates CD226 and CD96 checkpoints in CD8+ T c ells to improve PD-1 response in cancer. Signal Transduct Target Ther, 2021, 6, 313.
Liu, C., Zhou, F., Yan, Z., Shen, L., Zhang, X., He, F., Wang, H., Lu, X., Yu, K., Zhao, Y.*, Zhu, D.* Discovery of a novel, potent, and selective small-molecu le inhibitor of PD-1/PD-L1 interaction with robust in vivo anti-tumor efficacy. Br. J. Pharmacol., 2021, 178(13): 2651-2670.
Tian, E., Yu, M., Feng, M., Wang, Y., Xie, Q.*, Zhu, D.* RORγt agonist synergizes with CTLA-4 antibody to inhibit tumor growth through inhibition of Treg cells via TGF-β signaling in cancer. Pharmacol.Res., 2021, 172:105793.
Feng, M., Zhao, Z., Yang, M., Ji, J., Zhu, D.*, T-cell-based immunotherapy in colorectal cancer. Cancer Lett., 2021, 498(40): 201-209.
Feng, M., Jin, J., Xia, L., Xiao, T., Mei, S., Wang, X., Huang, X., Chen, J., Liu, M., Chen, C., Raf, S., Zhu, A., Feng, Y.*, Zhu, D.* Pharmacolo gical inhibition of β-catenin/BCL9 interaction overcomes resistance to immune checkpoint blockad es by modulating Treg cells. Sci. Adv., 2019, 5(5): 1-16.